ArticleScience translational medicine2018
An OX40/OX40L interaction directs successful immunity to hepatitis B virus.
Article in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.Hepatology (Baltimore, Md.) · 2021Trial
- PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.The Journal of clinical investigation · 2018Trial
- Host-directed immune therapies: a second front in the battle against sepsis.The Journal of clinical investigation · 2026Review
- A CD40-OX40 co-stimulatory circuit orchestrates protective CD4Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Interferon therapy for chronic hepatitis B in children: an immunological perspective.Frontiers in immunology · 2026Review
- Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis.Microbiology spectrum · 2023Article
- Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation.Frontiers in immunology · 2023Review
- Progress and Prospects of Non-Canonical NF-κB Signaling Pathway in the Regulation of Liver Diseases.Molecules (Basel, Switzerland) · 2022Review
- CD4Frontiers in immunology · 2022Review
- Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis.Journal of leukocyte biology · 2021Article
- Elevated soluble 4-1BB is associated with serum markers of hepatitis B virus in patients with chronic hepatitis B.World journal of clinical cases · 2021Article
- Noncanonical NF-κB Signaling Pathway in Liver Diseases.Journal of clinical and translational hepatology · 2021Review
- Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID-19.Immunological reviews · 2021Review
- Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.Hepatology (Baltimore, Md.) · 2021Article
- HBV-Specific CD8+ T-Cell Tolerance in the Liver.Frontiers in immunology · 2021Review
- Interplay Between Non-Canonical NF-κB Signaling and Hepatitis B Virus Infection.Frontiers in immunology · 2021Review
- Interferon Alpha Induces Multiple Cellular Proteins That Coordinately Suppress Hepadnaviral Covalently Closed Circular DNA Transcription.Journal of virology · 2020Article
- In Silico Prediction of Human Leukocytes Antigen (HLA) Class II Binding Hepatitis B Virus (HBV) Peptides in Botswana.Viruses · 2020Article
- Modified Alphavirus-Vesiculovirus Hybrid Vaccine Vectors for Homologous Prime-Boost Immunotherapy of Chronic Hepatitis B.Vaccines · 2020Article
- Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 5 institutions in 1 country.
Funding
Abstract
Depending on age of acquisition, hepatitis B virus (HBV) can induce a cell-mediated immune response that results in either cure or progressive liver injury. In adult-acquired infection, HBV antigens are usually cleared, whereas in infancy-acquired infection, they persist. Individuals infected during infancy therefore represent the majority of patients chronically infected with HBV (CHB). A therapy that can promote viral antigen clearance in most CHB patients has not been developed and would represent a major health care advance and cost mitigator. Using an age-dependent mouse model of HBV clearance and persistence in conjunction with human blood and liver tissue, we studied mechanisms of viral clearance to identify new therapeutic targets. We demonstrate that age-dependent expression of the costimulatory molecule OX40 ligand (OX40L) by hepatic innate immune cells is pivotal in determining HBV immunity, and that treatment with OX40 agonists leads to improved HBV antigen clearance in young mice, as well as increased strength of T cell responses in young mice and adult mice that were exposed to HBV when they were young and developed a CHB serological profile. Similarly, in humans, we show that hepatic OX40L transcript expression is age-dependent and that increased OX40 expression on peripheral CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.